UoLiverpool Confidence in Concept 2013
Lead Research Organisation:
University of Liverpool
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
Organisations
People |
ORCID iD |
Publications
Alhamdi Y
(2015)
Circulating Pneumolysin Is a Potent Inducer of Cardiac Injury during Pneumococcal Infection.
in PLoS pathogens
Garalla HM
(2018)
Matrix metalloproteinase (MMP)-7 in Barrett's esophagus and esophageal adenocarcinoma: expression, metabolism, and functional significance.
in Physiological reports
Henry BD
(2015)
Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice.
in Nature biotechnology
Naisbitt DJ
(2015)
Towards depersonalized abacavir therapy: chemical modification eliminates HLA-B*57 : 01-restricted CD8+ T-cell activation.
in AIDS (London, England)
Wright HL
(2017)
Neutrophil biomarkers predict response to therapy with tumor necrosis factor inhibitors in rheumatoid arthritis.
in Journal of leukocyte biology
Wright HL
(2017)
Low-density granulocytes: functionally distinct, immature neutrophils in rheumatoid arthritis with altered properties and defective TNF signalling.
in Journal of leukocyte biology
| Description | Biomarker-guided duration of Antibiotic Treatment in Children Hospitalised with confirmed or suspected bacterial infection (The BATCH Trial) |
| Amount | £1,638,609 (GBP) |
| Funding ID | HTA/15/188/42 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 02/2022 |
| Description | MICA: Development of a novel host blood test using TRanscripts to Identify bacterial Meningitis - TRIM test study |
| Amount | £791,702 (GBP) |
| Funding ID | MR/R015406/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2019 |
| End | 03/2022 |
| Title | ANTIVIRAL 4-(2-AMINO-6-HETEROCYLYL-9H-PURIN-9-YL)-2-CYCLOPENTENE-1 -METHANOL COMPOUNDS |
| Description | The present invention relates to certain antiviral compounds of formula I as defined herein that function as nucleoside reverse transcriptase inhibitors. The present invention also relates to processes for the preparation of these compounds, pharmaceutical compositions comprising them and to their use for the treatment of retroviral infections, and in particular their use in the treatment of HIV-1 virus. |
| IP Reference | WO2017021716 |
| Protection | Patent application published |
| Year Protection Granted | 2017 |
| Licensed | No |
| Impact | Actively working with the IP team to identify a new industrial partner and they plan to re-apply for MRC-DPFS funding. In addition the team were successful in securing funding from Innovate UK (£35K - ICURe award) to perform market research and horizon scanning work to determine likely routes to market for the diagnostic assay. Feedback indicated interest from diagnostics companies in both Human and Veterinary markets. |
| Title | DETECTION OF BACTERIAL INFECTION |
| Description | The present invention relates to methods of detecting and treating a bacterial infection, such as bacterial meningitis, and addresses the problem of misdiagnosis of bacterial infections. The medical use of antibacterial agents in the treatment of a bacterial infection in a subject identified by the methods of the invention is also described. The methods of the invention comprise assaying a sample from the subject to obtain data of the relative abundance of target molecules indicative of the expression of at least one gene pair, determining the presence or absence of a bacterial infection in the subject in dependence on the data, and optionally treating the subject with an antibacterial agent if required. |
| IP Reference | WO2017068347 |
| Protection | Patent application published |
| Year Protection Granted | 2017 |
| Licensed | No |
| Impact | Various follow-on awards and approach by the Foundation for Innovative Diagnostics (FIND), Geneva. They want to undertake a collaborative study to assess host marker accuracy in blood to distinguish bacterial from viral infection among fever patients from lower middle-income countries. FIND has access to appropriate patient sample sets. A collaborative agreement is being drafted. |
| Title | METHODS FOR PREDICTING RESPONSE TO ANTI-TNF THERAPY |
| Description | The present invention relates to a method for predicting the response of a patient suffering from an autoimmune or immune-mediated disorder to anti-TNF therapy based upon the expression of a Low Density Granulocyte gene or one or more interferon regulated biomarkers. Also provided is a kit for performing the invention, and related methods of treatment and monitoring response to treatment. |
| IP Reference | WO2017093750 |
| Protection | Patent application published |
| Year Protection Granted | 2017 |
| Licensed | No |
| Impact | Pending. |
| Title | PHARMACOLOGICALLY ACTIVE COMPOUNDS |
| Description | [origin: WO2015097475A1] The present invention relates to compounds of formula (I) shown below: wherein Q is as defined herein. The compounds of formula (I) act as selective positive allosteric modulators of strychnine-sensitive alpha 1-glycine receptors. The present invention further relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of diseases or conditions in which strychnine-sensitive alpha 1-glycine receptor activity is implicated (such as, for |
| IP Reference | EP3087055 |
| Protection | Patent granted |
| Year Protection Granted | 2016 |
| Licensed | No |
| Impact | We are currently in licensing negotiations (heads-of-terms stage) with two large pharmaceutical companies and in the process of contacting a suitable venture capital investor. |
| Title | PHARMACOLOGICALLY ACTIVE COMPOUNDS |
| Description | wherein Q is as defined herein. The compounds of formula I act as selective positive allosteric modulators of strychnine-sensitive alpha 1-glycine receptors. The present invention further relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of diseases or conditions in which strychnine-sensitive alpha 1-glycine receptor activity is implicated (such as, for example, chronic pain. The present invention also relates to processes for the preparation of these compounds and to pharmaceutical compositions comprising them. |
| IP Reference | US2016318947 |
| Protection | Patent granted |
| Year Protection Granted | 2016 |
| Licensed | No |
| Impact | We are currently in licensing negotiations (heads-of-terms stage) with two large pharmaceutical companies and in the process of contacting a suitable venture capital investor. |